Several other equities research analysts also recently weighed in on the company. Northland Securities reaffirmed a buy rating and issued a $7.00 target price on shares of STRATA Skin Sciences in a research report on Tuesday, May 14th. HC Wainwright set a $5.00 target price on STRATA Skin Sciences and gave the stock a buy rating in a research report on Monday, July 8th. Finally, Zacks Investment Research downgraded STRATA Skin Sciences from a hold rating to a sell rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $4.92.
Shares of NASDAQ SSKN opened at $2.39 on Thursday. STRATA Skin Sciences has a 1-year low of $2.01 and a 1-year high of $3.88. The business has a 50-day moving average of $2.60 and a 200-day moving average of $2.71.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.
See Also: Understanding Analyst Recommendations
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.